Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

- Company Advancing Lead Candidate HspE7 into Phase 2 Clinical Trial in

2008 -

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today financial results for the year ended December 31, 2007, and highlighted the corporate milestones achieved during the period.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

During 2007, the Company achieved the following corporate milestones:

Progress on Lead Candidate HspE7:

-- Made significant progress on the Company's Phase 1 cervical dysplasia

clinical trial examining the safety of new HspE7 leading to the recent

completion of enrollment and initial dosing of the last cohort in this

trial

-- Presented preclinical data at International Papillomavirus conference

demonstrating that co-administering HspE7 with certain adjuvants

promotes more potent responses than HspE7 alone

-- Demonstrated ability to elicit long-lasting tumor protection in vivo

suggesting that HspE7 may have utility in HPV-related diseases

-- Announced data from NCI-sponsored trial in cervical dysplasia showing

78 percent of patients achieved complete response or reduction of

lesion size by more than 50 percent

Corporate and Financial Achievements:

-- Strengthened the Management team with the addition of Richard Lai Fatt,

Ph.D., as Vice President of Corporate Development, and David Duncan,

Jr., as Vice President of Finance

-- Appointed Sandford D. Smith, President of the International Group and

Executive Vice President of Genzyme Corporation, to the Board of

Directors

-- Assembled a distinguished group of international experts for the

Company's Clinical and Scientific Advisory Board

'/>"/>
SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 In preparation ... Texas -based cybersecurity company focused on authentication and ... will support the ability to generate a OTP through ... As a pioneer of user-based RFID authentication, 2FA,s solutions ... physical access, for many years. RFID authentication is broadly ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)... Sept. 15, 2014  iVinci Health LLC, the company ... Revenue Management system, branded as VisitPay®, has successfully closed ... the launch of a new extension to VisitPay® – ... easy and convenient way for patients to manage their ... by them and their families. The new ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... , SANTA CLARA, Calif. , Jan. 28 Coherent, Inc. (Nasdaq: COHR ), a world leader in providing ... , FINANCIAL HIGHLIGHTS , , , , , ... Three Months Ended, ... ------------------, GAAP Results ...
... , MADRID , Jan. 28 The ... category goes to physicist and chemist Richard N. Zare , ... , of the University of Maryland , for their independent, ... unraveled secrets of nature,s building blocks and the underlying interactions between ...
... ... Webster Cavenee, Ph.D., and Frank Furnari, Ph.D., along with their team at ... Diego School of Medicine, have recently discovered one way that brain tumors ... stop tumor growth. This breakthrough discovery revealed a new cellular mechanism ...
Cached Biology Technology:Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 2Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 3Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 4Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 5Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 6Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 7Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 8Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 9Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 10Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 11Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 12Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 2Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 3Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 4Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 5Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 6Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 7NFCR Scientists Discover Brain Tumor's “Escape Path” 2NFCR Scientists Discover Brain Tumor's “Escape Path” 3
(Date:9/15/2014)... allow us to better understand how the fish ... and provide the type of environmental data to ... siting of protected areas," said Paula Whitfield, a ... Ocean Science (NCCOS) and lead author of the ... the temperate-tropical transition zone, where historically, both temperate ...
(Date:9/15/2014)... 500 million years after it formed may have been ... continents and active crustal plates. , This alternate view ... gained substantial new support from the first detailed comparison ... years ago with those formed contemporaneously in Iceland, which ... early Earth. , The study was conducted by a ...
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
Breaking Biology News(10 mins):Study finds warming Atlantic temperatures could increase range of invasive species 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... ovarian ,chocolate, cysts for the brown liquid they contain, ... common, which can cause ongoing pain and complications. A ... and effective remedy the oral contraceptive pill (OCP). ... Reilly from Auckland, New Zealand, highlight a trial published ...
... AUGUSTA, Ga. - New drugs that are helping fight ... cardiovascular disease, Medical College of Georgia researchers said. Cancer ... as a cause. Heat shock protein 90 inhibitors as a ... director of MCG,s Vascular Biology Center. "I think hsp90 ...
... use of Chinese wolfberries to improve vision deficiencies that are ... assistant professor of human nutrition, is studying wolfberries and their ... that the fruit can lower the oxidative stress that the ... would not say that wolfberries are a medicine, but they ...
Cached Biology News:New cancer therapy may fight cardiovascular disease 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 3
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Biology Products: